Sangamo raises ~$25M in underwritten offering of common stock and warrants; amends prior warrants

SANGAMO THERAPEUTICS, INC

Offering of 35.19M shares + pre-funded warrants for 17.79M shares, each with a purchase warrant for 52.98M shares.
Combined price per share+ warrant is $0.4719; pre-funded warrant+ warrant at $0.4619; gross proceeds ~$25M.
Existing warrants held by investor repriced from $1.00 to $0.4719 and expiration extended to 5.5 years from closing.
Closing expected February 4, 2026; proceeds for general corporate purposes.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

SANGAMO THERAPEUTICS, INC entered into Underwriting Agreement with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC valued at approximately $25.0 million (effective 2026-02-03).

Action: entry
Agreement: underwriting
Counterparty: Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC
Value: approximately $25.0 million
Effective: 2026-02-03

Exact text from the filing

On February 3, 2026, Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC

View on SEC.gov

319 material agreements filed in the last 30 days. Browse all material agreements →

SANGAMO THERAPEUTICS, INC filing history →

Source: SEC EDGAR

accession 0001193125-26-036792

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.